A deep learning model for drug screening and evaluation in bladder cancer organoids.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: The model improved organoid-image segmentation over classical algorithms and was used to compare drug-treated organoid growth over time.
Technology: ACU2Net/U2Net-family segmentation measured bladder-cancer organoid growth after retinoic-acid and B0107 exposure.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- ACU2Net/U2Net-family segmentation measured bladder-cancer organoid growth after retinoic-acid and B0107 exposure.
- Limitation / still unknown
- A 200-image dataset with expert pixel labels and train/validation/test partitions; organoid lines and assay conditions limit biological generalization.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1064548/full · https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1064548/full#s2 · https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1064548/full#s3–s4 · https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1064548/full#s2–s4 · https://pubmed.ncbi.nlm.nih.gov/37168370/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.